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Prof Uziel Beller 
Editor in Chief  
International Journal of Gynecological Cancer 
 
Dear Sir, 
Increasing evidence that the fallopian tube plays a central role in the origin of epithelial ovarian 
cancer(OC),1 the establishment of serous tubal insitu carcinoma(STIC) as a precursor lesion and lack 
of mortality benefit from screening have given a huge impetus to exploring surgical prevention 
strategies. Opportunistic Bilateral Salpingectomy(OBS) has been recommended as an OC prevention 
strategy for premenopausal women who have completed their family and are undergoing tubal 
sterilization or benign gynaecological surgery. A number of institutions/clinicians led by the group in 
British Columbia2 have changed clinical protocols to incorporate this practice. Recent guidelines 
from the ACOG3 and SGO4 recommend OBS be considered as an OC prevention strategy while at the 
same time highlighting the need/importance for further trials to confirm the validity and benefit of 
this approach.3 Recently published retrospective analysis of Swedish5 and Danish6 population based 
data provide initial evidence of benefit from salpingectomy with a 35%-42% reduction in OC risk 
reported, although the confidence intervals are wide and the number of OC cases in some subgroups 
is small. The Swedish study was also limited by lack of control for the contraceptive pill. The biology 
and etiopathogenesis of OC is complex and our understanding of this remains incomplete. OBS will 
not prevent cancers that arise outside the tube. Only 15-60% of high-grade serous cancers (HGSC) 
have STIC lesions. The natural history of STICs and the trigger/rate limiting step in the development 
of OC is unknown. Recent data indicate the presence of different types of HGSC having different 
types of STICs, with different biology, lag phases, progression rates, outcomes and BRCA status.7 
Hysterectomy with tubo-ovarian conservation and tubal sterilization per-se are associated with a 
30% reduction in OC risk,8, 9 and the additional benefit from salpingectomy above this has not been 
precisely defined. Prospective high quality data for OBS showing a reduction in OC risk are lacking 
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and the long term impact of salpingectomy on health outcomes including ovarian function and 
menopause is unknown.  
Through the RCOG we undertook a 19-item anonymised web-based survey of UK obstetricians and 
gynaecologists (O&Gs), regarding their views and practice of OBS. Of the 395 respondents, 53% were 
men and 47% women; 76.9% were consultants/post-CCT and 19.3% were trainees. 62.5% were 
general O&Gs, 18% were general gynaecologists and 17% subspecialists (gynaecological 
subspecialties). We found reasonable awareness with ~75% having heard of OBS and 61% agreeing 
with the tubal hypothesis. Awareness in the UK is slightly lower than reports from Canada where 
90% had heard of OBS.10 There was broad support with 33% respondents always/most of the time 
performing OBS and 50.2% supporting introduction into routine clinical practice. However, this was 
lower than levels of support reported in Canada and Ireland of 68%10 and 74-80% respectively.11 At 
the same time, 53% of UK O&Gs felt that OBS should be offered only within a clinical trial, with a 
high 89% respondents expressing support for a clinical trial to evaluate the benefit and short/long 
term outcomes. This level of support raises the possibility of prospective validation of OBS in the 
setting of a randomised trial in the UK. There may be greater concern in the UK regarding 
widespread clinical implementation with lack of data on additional reduction in OC risk (78%), RCT 
evidence of benefit (76%), and impact on ovarian function (65%) highlighted as leading factors 
limiting its introduction.  
 
Whether OBS will lead to early menopause is unknown. Available data on ovarian function post 
salpingectomy are few/limited and restricted to short term outcomes of hormonal levels and ovarian 
blood flow indices.12 However, these correlate with ovarian reserve in relation to fertility rates, 
oocyte retrieval and IVF outcomes,13 and are not predictive of risk for premature menopause. There 
are no validated hormonal cut-points that predict the length of the menopausal transition or final 
menstrual period.14, 15 Assessment of a longitudinal trend/change in hormonal levels (and menstrual 
periods) over a period of years following OBS is critically important to assess impact on menopause. 
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This is relevant given the detrimental impact of premature surgical menopause on cardiovascular, 
bone, neurological heath and mortality.16  
 
Another important issue of concern is potential training implications for clinicians/O&G trainees in 
the UK: highlighted by 21%/49% respectively. 38% of less experienced (<8years post MRCOG) 
compared to 12% more experienced (>23years post MRCOG) clinicians felt they would benefit from 
additional training (p<0.005). This is higher compared to 15% Canadian O&Gs who felt additional 
surgical training would be beneficial.10 
 
Views/practice also varies by experience and place of work. More experienced UK clinicians (63% of 
highest quartile vs 26% in lowest quartile) felt that OBS should only be introduced within a clinical 
trial(p=0.0002). Clinicians in university/teaching hospitals (U/TH) compared to district general 
hospitals(DGH) were more likely to support the tubal hypothesis (66% vs 56%, p=0.008), perform 
OBS (43% vs 28%, p=0.034) and support its introduction into clinical practice (56% vs 44% p=0.043). 
While clinicians working at DGH compared to U/TH report greater concerns for lack of long term 
outcome data (p=0.019), RCT evidence of benefit (p=0.011) and implications for training for self 
(p=0.035) and trainees (p=0.043).  
 
We found a significant lack of awareness regarding the reduction in OC risk associated with tubal 
ligation and hysterectomy itself with 72-76% respondents being unaware of this. It is possible that 
enthusiasm for OBS outside a study may be further tempered had these facts been better known. A 
6% regret/reversal rate has been reported for women undergoing sterilization.17 This emerged as 
another important issue given the irreversibility of salpingectomy compared to ligation. Paucity of 
cost-effectiveness data was considered a limitation by 45% respondents. A recent study from British 
Columbia suggests OBS may be cost-effective assuming a ‘50%’ reduction in OC risk and ‘no’ 
detrimental impact on menopause/ovarian function.18 However, prospective data confirming these 
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levels of beneficial outcomes along with utility scores for salpingectomy are lacking, maintaining 
uncertainty on this issue. Further prospective studies on cost-effectiveness of OBS are needed. 
There is a pressing need to develop consensus on whether or not OBS should be offered primarily 
within a clinical trial in the UK. This may also be of relevance to other countries debating this issue. 
While a number of charities, patient groups and learned societies3, 4 have advocated offering OBS, 
the need and importance of further trials has also been recognised,3 with some suggesting this be 
offered only within a clinical trial.19 It is important to ensure that any introduction of OBS into clinical 
practice does not hinder/prevent collection of prospective good quality evidence to validate its 
efficacy in preventing OC and understand implications on long-term health outcomes. A cohort study 
will not adequately answer the question of additional impact of OBS over standard surgery. A two 
arm RCT with OC as the primary outcome would require a multicentre international study of 
~100,000 women (51,600/arm) and 10year follow-up (for a 30% difference between arms, 80% 
power, α=0.05, assuming annual OC incidence of 30/100,000). This will be difficult to fund. A 
pragmatic and plausible way forward which addresses a key issue would be a RCT with menopause 
as the primary outcome. A sample size of 7026 women (3513/arm) will detect a HR=1.2 or 4690 
(2345/arm) a HR=1.25 (90% power, α=0.05; assuming: 20% event rate, 10% withdrawal rate). This 
will also address various secondary outcomes highlighted above. Moreover, it is important that all 
cases of OBS undertaken clinically at benign surgery be properly recorded using a separate hospital 
code to enable linkage for long term follow-up and data collection. The strength of the argument for 
change in practice needs to be driven by the magnitude of the additional benefit of OBS on OC risk, 
weighed against the implications for logistics of delivery, impact on training needs, potential 
complications, additional costs, and long-term health outcomes of early menopause and its 
consequences. The RCOG and its subspecialist societies as well as international bodies like ESGO and 
IGCS have an important role to play in this.  
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